This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): ACT-050089, Veletri
Tezosentan is a dual action endothelin-1 receptor inhibitor. Tezosentan's benefits in the failing heart are believed to result from its ability to indirectly improve contractility while decreasing pulmonary capillary wedge pressure (PCWP).
Veletri was previously the proposed brand name for tezosentan. Actelion announced the discontinuation of the tezosentan development program in April 2008, and in August 2010, Actelion was granted approval of the Veletri brand name for epoprostenol for injection therapy.
Revenue splits for this drug are BioMedTracker estimates.
Actelion and Roche
Actelion licensed tezosentan from Hoffmann-La Roche in 1998. Actelion partnered with Genentech in February 2000 to co-promote Veletri in the U.S. Genentech can opt out of the partnership after the conclusion of phase III trials.
Genentech and Roche
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Roche Holding AG
Pink Sheet Actelion/Genentech tezosentan
Pink Sheet Actelion Stops Tezosentan Trial
Additional information available to subscribers only: